- Home
- VMC vs BIIB Comparison
VMC vs BIIB Comparison
Compare VMC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMC
- BIIB
- Stock Information
- Founded
- VMC 1909
- BIIB 1978
- Country
- VMC United States
- BIIB United States
- Employees
- VMC N/A
- BIIB N/A
- Industry
- VMC Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- VMC Industrials
- BIIB Health Care
- Exchange
- VMC Nasdaq
- BIIB Nasdaq
- Market Cap
- VMC 31.4B
- BIIB 25.1B
- IPO Year
- VMC N/A
- BIIB 1991
- Fundamental
- Price
- VMC $263.15
- BIIB $146.47
- Analyst Decision
- VMC Strong Buy
- BIIB Buy
- Analyst Count
- VMC 14
- BIIB 26
- Target Price
- VMC $283.92
- BIIB $248.00
- AVG Volume (30 Days)
- VMC 694.7K
- BIIB 1.4M
- Earning Date
- VMC 02-14-2025
- BIIB 02-11-2025
- Dividend Yield
- VMC 0.70%
- BIIB N/A
- EPS Growth
- VMC 2.90
- BIIB 10.05
- EPS
- VMC 6.35
- BIIB 11.06
- Revenue
- VMC $7,398,300,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- VMC N/A
- BIIB N/A
- Revenue Next Year
- VMC $10.05
- BIIB N/A
- P/E Ratio
- VMC $41.46
- BIIB $13.24
- Revenue Growth
- VMC N/A
- BIIB N/A
- 52 Week Low
- VMC $218.37
- BIIB $145.07
- 52 Week High
- VMC $298.31
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- VMC 33.99
- BIIB 24.17
- Support Level
- VMC $274.08
- BIIB $148.60
- Resistance Level
- VMC $277.67
- BIIB $154.24
- Average True Range (ATR)
- VMC 5.88
- BIIB 3.71
- MACD
- VMC -3.12
- BIIB -0.37
- Stochastic Oscillator
- VMC 15.43
- BIIB 7.48
About VMC Vulcan Materials Company (Holding Company)
Vulcan Materials is the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). Its largest markets include Texas, California, Virginia, Tennessee, Georgia, Florida, North Carolina, and Alabama. In 2023, Vulcan sold 234.3 million tons of aggregates, 13.4 million tons of asphalt mix, and 7.5 million cubic yards of ready-mix. As of Dec. 31, 2022, the company had nearly 16 billion tons of aggregates reserves.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.